Nascent Biotech Inc (NBIO)

$0.00 +0.00 (48.28%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 5,100
Avg Vol 48,608
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 3%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and t...

Industry: Biotechnology
Sector: Healthcare
Phone: 612 961 5656
Address:
631 US Hwy 1, Suite 407, North Palm Beach, United States
ok2buy
ok2buy Nov. 13 at 5:18 PM
$NBIO If there is one lesson to be learned over the last couple days, this one can turn one way or the other very quickly. Still wishing the faithful longs the best of luck./
0 · Reply
J1983
J1983 Nov. 13 at 3:00 PM
$NBIO Back to the shelf for this one. Oh well, I’ve long let go of the money I’ve lost here. It would’ve been nice to see Pritumumab get its chance to save lives, but it looks like it’s going nowhere.
0 · Reply
ok2buy
ok2buy Nov. 13 at 2:50 PM
$NBIO The joy is short-lived. 5,000 shares sold @ $0.0002/share./
1 · Reply
J1983
J1983 Nov. 12 at 9:26 PM
$NBIO If PTB is backed by significant financial support or if it is sold to a large company that can fund Phase 2 & 3, then $1 is definitely possible. In 2023, Marble Arch Research specified a price range of $0.60-$2.84. https://www.nascentbiotech.com/marble-arch-research-what-is-pritumumab-and-how-it-works/
0 · Reply
ok2buy
ok2buy Nov. 12 at 6:26 PM
$NBIO From a new poster, asking if $1 is possible. From the company's info, the Glioblastoma market is expected to be $5.68 billion in the next 3-5 years. Lots of ifs, but if the drug can demonstrate efficacy, we have the right partner or the company outright sells, who knows?? Seems like a crazy number today, but do the math, without any dilution to shares, the share price would be unimagineable. But I'm getting ahead of myself. Best of luck to the longs./
0 · Reply
ok2buy
ok2buy Nov. 12 at 3:19 PM
$NBIO Quiet today so far, nothing traded./
0 · Reply
ok2buy
ok2buy Nov. 12 at 2:09 PM
$NBIO This study (Mar/2025), I believe validates pritumumab as a viable treatment for brain cancer. It looks to me like this is third party research. This could help give the company the necessary leverage to relist trading for all, (currently expert trading only designation?) and open up exciting new potential for partnerships or sale of the asset. These are my opinions only! Here is the link. Best of luck to the faithful longs./ok2 https://www.nature.com/articles/s41598-025-95360-9
0 · Reply
ok2buy
ok2buy Nov. 12 at 1:39 PM
$NBIO J1983 - Looking at the last 2 days of trading: Nov.10/25, $0.09, 40,000 shares sold, Nov.11/25, High $0.1345, Low $0.08, Close $0.084, 211,000 shares sold. Clearly someone is willing to buy shares and this demonstrates that there is value here. I remember reading somewhere that the company was looking for $0.25/share in unlocked potential. I guess we'll see. A call to my broker my shed some light on the trading status. Obviously someone can buy and sell./
0 · Reply
J1983
J1983 Nov. 12 at 1:25 PM
$NBIO Thanks ok2buy - I hope so too. I know you’ve been in this longer than I have and I’ve been here 5 years. I’m hoping this amazing drug gets it shot!
0 · Reply
ok2buy
ok2buy Nov. 12 at 1:23 PM
$NBIO J1983 - I posted a few days back that I thought something was up. Someone was accumulating shares on the cheap. I tried to buy, I can place an order, but my trading platform ultimately rejects the order. Perhaps, either 1) management has secured new funding or 2) there is a sale of the company or it's assets. Either way, I am hoping that this is good news for existing shareholders. I am going to try to see if we are back in compliance and can be traded again. Best of luck to the faithful longs./
0 · Reply
Latest News on NBIO
No data available.
ok2buy
ok2buy Nov. 13 at 5:18 PM
$NBIO If there is one lesson to be learned over the last couple days, this one can turn one way or the other very quickly. Still wishing the faithful longs the best of luck./
0 · Reply
J1983
J1983 Nov. 13 at 3:00 PM
$NBIO Back to the shelf for this one. Oh well, I’ve long let go of the money I’ve lost here. It would’ve been nice to see Pritumumab get its chance to save lives, but it looks like it’s going nowhere.
0 · Reply
ok2buy
ok2buy Nov. 13 at 2:50 PM
$NBIO The joy is short-lived. 5,000 shares sold @ $0.0002/share./
1 · Reply
J1983
J1983 Nov. 12 at 9:26 PM
$NBIO If PTB is backed by significant financial support or if it is sold to a large company that can fund Phase 2 & 3, then $1 is definitely possible. In 2023, Marble Arch Research specified a price range of $0.60-$2.84. https://www.nascentbiotech.com/marble-arch-research-what-is-pritumumab-and-how-it-works/
0 · Reply
ok2buy
ok2buy Nov. 12 at 6:26 PM
$NBIO From a new poster, asking if $1 is possible. From the company's info, the Glioblastoma market is expected to be $5.68 billion in the next 3-5 years. Lots of ifs, but if the drug can demonstrate efficacy, we have the right partner or the company outright sells, who knows?? Seems like a crazy number today, but do the math, without any dilution to shares, the share price would be unimagineable. But I'm getting ahead of myself. Best of luck to the longs./
0 · Reply
ok2buy
ok2buy Nov. 12 at 3:19 PM
$NBIO Quiet today so far, nothing traded./
0 · Reply
ok2buy
ok2buy Nov. 12 at 2:09 PM
$NBIO This study (Mar/2025), I believe validates pritumumab as a viable treatment for brain cancer. It looks to me like this is third party research. This could help give the company the necessary leverage to relist trading for all, (currently expert trading only designation?) and open up exciting new potential for partnerships or sale of the asset. These are my opinions only! Here is the link. Best of luck to the faithful longs./ok2 https://www.nature.com/articles/s41598-025-95360-9
0 · Reply
ok2buy
ok2buy Nov. 12 at 1:39 PM
$NBIO J1983 - Looking at the last 2 days of trading: Nov.10/25, $0.09, 40,000 shares sold, Nov.11/25, High $0.1345, Low $0.08, Close $0.084, 211,000 shares sold. Clearly someone is willing to buy shares and this demonstrates that there is value here. I remember reading somewhere that the company was looking for $0.25/share in unlocked potential. I guess we'll see. A call to my broker my shed some light on the trading status. Obviously someone can buy and sell./
0 · Reply
J1983
J1983 Nov. 12 at 1:25 PM
$NBIO Thanks ok2buy - I hope so too. I know you’ve been in this longer than I have and I’ve been here 5 years. I’m hoping this amazing drug gets it shot!
0 · Reply
ok2buy
ok2buy Nov. 12 at 1:23 PM
$NBIO J1983 - I posted a few days back that I thought something was up. Someone was accumulating shares on the cheap. I tried to buy, I can place an order, but my trading platform ultimately rejects the order. Perhaps, either 1) management has secured new funding or 2) there is a sale of the company or it's assets. Either way, I am hoping that this is good news for existing shareholders. I am going to try to see if we are back in compliance and can be traded again. Best of luck to the faithful longs./
0 · Reply
Enstant
Enstant Nov. 12 at 1:35 AM
$NBIO will this be $1?
0 · Reply
J1983
J1983 Nov. 11 at 7:26 PM
$NBIO What’s going on?!
1 · Reply
ok2buy
ok2buy Nov. 7 at 4:09 PM
$NBIO It does appear that someone is bottom feeding NBIO. Unfortunately my trading platform will not allow me to buy anymore, so I guess I am sitting on what I already own. I still believe there is value here that has not been unlocked (but maybe never will)! Best of luck to those who are still here and holding shares with me./ok2
2 · Reply
DrTdawg
DrTdawg Sep. 11 at 11:29 PM
$NBIO alright gang. Anyone else waking up to this activity? Any ideas?
1 · Reply
J1983
J1983 Aug. 28 at 7:04 PM
$NBIO anything? 🦗
0 · Reply
4sprouts
4sprouts Jul. 17 at 11:14 AM
$NBIO Could this bring hope for pritumumab and advancement/funding of phase II?! The ORPHAN CURES ACT was signed into law, protecting important incentives for researching and developing rare disease! Would love to see a rebirth in research for rare disease such as glioblastoma for those who desperately need it! https://www.wsj.com/opinion/orphan-drugs-gop-budget-bill-price-controls-inflation-reduction-act-19520a0d?gaa_at=eafs&gaa_n=ASWzDAgTtQ7GI9UyNbLPA9B3nUCl45jObfPcxX0TQ1uyxbB8fQTdSo_077N3cCzoDQ%3D%3D&gaa_ts=6878d85b&gaa_sig=GT4ogyfr-GZVklt6b81rmL14OcxxvqDLqFulLG45O_WmbawIVviHmXSGcPxXVWyL0vgYYFxFD87gntt2CJo4bA%3D%3D
2 · Reply
4sprouts
4sprouts Jul. 5 at 5:49 PM
$NBIO 1. https://www.nascentbiotech.com/message-from-senior-management/ 2. https://www.nascentbiotech.com/letter-to-shareholders-from-sean-carrick/
2 · Reply
J1983
J1983 May. 9 at 2:46 PM
$NBIO @ok2buy The .0001 gives you hope? It’s over, my friend. We had our chance and should’ve sold years ago when it hit .45. I’ll always regret not selling.
0 · Reply
ok2buy
ok2buy May. 7 at 5:21 PM
$NBIO Nope. Don't believe this is done./
1 · Reply
J1983
J1983 May. 3 at 6:49 PM
$NBIO @4sprouts I don’t think this is good news at all for NBIO and us investors: “The CHO derived antibody discussed here is considered a new antibody and an IND has been approved by the FDA to commence dose-esclation clinical trial will be evaluated.” This is a new FDA approved antibody based off PTB. Makes sense why NBIO has given up. Write it off as a loss, it’s over.
1 · Reply
4sprouts
4sprouts May. 2 at 10:24 PM
$NBIO pritumumab was featured in the medical journal Nature in March 2025. It included contributing author Santosh Kesari, medical consultant and equity holder in Nascent Biotech. Hopefully there will be renewed interest in bringing pritumumbab into active Phase II trials and continue to demonstrate its potential. Would be nice to hear from the company with future course of action. Open access Published: 25 March 2025 Characterization of pritumumab in murine models and primate safety study https://www.nature.com/articles/s41598-025-95360-9
0 · Reply
J1983
J1983 Apr. 29 at 8:08 PM
$NBIO Who’s been buying at .03?
1 · Reply